Abstract:Glucagon-secreting pancreatic a-cells play pivotal roles in the development of diabetes. Glucagon promotes insulin secretion from I3-cells. However, the long-term effect of glucagon on the function and phenotype of I3-cells had remained elusive. In this study, we found that long-term glucagon intervention or glucagon intervention with the presence of palmitic acid downregulated I3-cell-specific markers and inhibited insulin secretion in cultured I3-cells. These results suggested that glucagon induced I3-cell dedifferentiation under pathological conditions. Glucagon blockage by a glucagon receptor (GCGR) monoclonal antibody (mAb) attenuated glucagon-induced I3-cell dedifferentiation. In primary islets, GCGR mAb treatment upregulated I3-cell-specific markers and increased insulin content, suggesting that blockage of endogenous glucagon-GCGR signaling inhibited I3-cell dedifferentia-tion. To investigate the possible mechanism, we found that glucagon decreased FoxO1 expression. FoxO1 inhibitor mimicked the effect of glucagon, whereas FoxO1 overexpression reversed the glucagon-induced I3-cell dedifferentiation. In db/db mice and I3-cell lineage-tracing diabetic mice, GCGR mAb lowered glucose level, upregulated plasma insulin level, increased I3-cell area, and inhibited I3-cell dedifferentiation. In aged I3-cell-specific FoxO1 knockout mice (with the blood glucose level elevated as a dia-betic model), the glucose-lowering effect of GCGR mAb was attenuated and the plasma insulin level, I3-cell area, and I3-cell dedif-ferentiation were not affected by GCGR mAb. Our results proved that glucagon induced I3-cell dedifferentiation under pathological conditions, and the effect was partially mediated by FoxO1. Our study reveals a novel cross talk between a- and I3-cells and is helpful to understand the pathophysiology of diabetes and discover new targets for diabetes treatment.NEW & NOTEWORTHY Glucagon-secreting pancreatic a-cells can interact with I3-cells. However, the long-term effect of gluca-gon on the function and phenotype of I3-cells has remained elusive. Our new finding shows that long-term glucagon induces I3-cell dedifferentiation in cultured I3-cells. FoxO1 inhibitor mimicks whereas glucagon signaling blockage by GCGR mAb reverses the effect of glucagon. In type 2 diabetic mice, GCGR mAb increases I3-cell area, improves I3-cell function, and inhibits I3-cell de-differentiation, and the effect is partially mediated by FoxO1.

Glucagon Receptor Antagonist Upregulates Circulating GLP-1 Level by Promoting Intestinal L-cell Proliferation and GLP-1 Production in Type 2 Diabetes

Glucagon Receptor Antagonism Promotes the Production of Gut Proglucagon-Derived Peptides in Diabetic Mice.

Antagonistic Glucagon Receptor Antibody Promotes Α-Cell Proliferation and Increases Β-Cell Mass in Diabetic Mice

Glucagon Acting at the GLP-1 Receptor Contributes to β-Cell Regeneration Induced by Glucagon Receptor Antagonism in Diabetic Mice

115-LB: Liver-Derived FGF21 Mediates the Promoting Effect of Glucagon Receptor Antagonism on Beta-Cell Regeneration in Type 2 Diabetic Mice

Γ-Aminobutyric Acid Modulates Α-Cell Hyperplasia but Not Β-Cell Regeneration Induced by Glucagon Receptor Antagonism in Type 1 Diabetic Mice

Combination of GLP-1 Receptor Activation and Glucagon Blockage Promotes Pancreatic Β-Cell Regeneration in Situ in Type 1 Diabetic Mice

Glucagon receptor monoclonal antibodies: A new strategy for diabetes pharmacotherapy

Glucagon Potentiates Insulin Secretion Via β-Cell GCGR at Physiological Concentrations of Glucose

Glucagon Potentiates Insulin Secretion Via Beta-Cell Gcgr At Physiological Concentrations Of Glucose

Pro--cell-derived -cells contribute to -cell neogenesis induced by antagonistic glucagon receptor antibody in type 2 diabetic mice

Glucagon receptor blockage inhibits ?-cell dedifferentiation through FoxO1

Glucagon Switches between GLP-1 and Glucagon Receptors in Normal and Hyperglycemic Mice

Fatty acid β‐oxidation and mitochondrial fusion are involved in cardiac microvascular endothelial cell protection induced by glucagon receptor antagonism in diabetic mice

Glucagon receptor antagonism increases mouse pancreatic δ-cell mass through cell proliferation and duct-derived neogenesis

Disruption of the Glucagon Receptor Increases Glucagon Expression Beyond Α-Cell Hyperplasia in Zebrafish

Myeloid-Derived Growth Factor Promotes Intestinal Glucagon-Like Peptide-1 Production in Male Mice with Type 2 Diabetes.

Novel GLP-1 Analog Supaglutide Stimulates Insulin Secretion in Mouse and Human Islet Beta-Cells and Improves Glucose Homeostasis in Diabetic Mice.

1612-P: Energetic Contributions of GLP1 and GCGR Activity in GLP1/GIP/GCGR Triagonism

GLP-1 Analog Liraglutide Enhances Proinsulin Processing in Pancreatic Β-Cells Via a PKA-dependent Pathway.

Hepatic Glucagon Receptor Binding and Glucose-Lowering in Vivo by Peptidyl and Non-Peptidyl Glucagon Receptor Antagonists.